Cummins Inc. (NYSE:CMI) is a global leader in the design, manufacture, and distribution of engines, filtration, and power generation products. The company serves customers in over 190 countries and territories through a network of approximately 600 company-owned and independent distributor locations and over 7,600 dealer locations. Cummins competes with companies like Caterpillar and General Electric in the industrial sector.On November 25, 2025, Steven Fisher from UBS set a price target of $500 for CMI. At ...

LATAM (LTM) closed the last trading session at $45.33, gaining 1.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $56.73 indicates a 25.2% upside potential.The average comprises four short-term price targets ranging from a low of $50.90 to a high of $60.00, with a standard deviation of $4.32. While the lowest estimate indicates an increase of 12.3% from the current price level, t ...

Shares of Profound Medical (PROF) have gained 6.3% over the past four weeks to close the last trading session at $6.23, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $12.31 indicates a potential upside of 97.6%.The average comprises four short-term price targets ranging from a low of $11.00 to a high of $15.25, with a standard deviation of $2.01. While the lowest estimate indi ...

Shares of Foghorn Therapeutics Inc. (FHTX) have gained 23.3% over the past four weeks to close the last trading session at $5.02, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $11.71 indicates a potential upside of 133.3%.The mean estimate comprises seven short-term price targets with a standard deviation of $2.06. While the lowest estimate of $9.00 indicates a 79.3% increase ...

Shares of Amazon (AMZN) have gained 10.2% over the past four weeks to close the last trading session at $234.69, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $294.4 indicates a potential upside of 25.4%.The average comprises 55 short-term price targets ranging from a low of $230.00 to a high of $340.00, with a standard deviation of $21.18. While the lowest estimate indicates ...

Core Viewpoint - Day One Biopharmaceuticals, Inc. (DAWN) has seen a 2.3% increase in share price over the past four weeks, closing at $7.04, with analysts suggesting a potential upside of 234.7% based on a mean price target of $23.56 [1] Price Targets - The average price target from nine analysts ranges from a low of $16.00 to a high of $34.00, with a standard deviation of $5.68, indicating a potential increase of 127.3% to 383% from the current price [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates - Analysts are optimistic about DAWN's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.6%, with one estimate moving higher and no negative revisions [12] Zacks Rank - DAWN currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which serves as a strong indicator of potential upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of the extent of potential gains, it does provide a useful guide for the direction of price movement [14]

Core Viewpoint - MBX Biosciences, Inc. (MBX) shares have increased by 2.6% over the past four weeks, closing at $17.96, with a potential upside of 228.5% based on Wall Street analysts' mean price target of $59 [1] Price Targets - The average of eight short-term price targets ranges from a low of $30.00 to a high of $84.00, with a standard deviation of $17.91, indicating variability among analysts [2] - The lowest estimate suggests a 67% increase from the current price, while the highest estimate indicates a 367.7% upside [2] Analyst Consensus and Earnings Estimates - Analysts show strong agreement that MBX will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] - Over the last 30 days, one earnings estimate has increased, leading to a 3.8% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank - MBX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside [13] Price Movement Guidance - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a useful guide for the direction of price movement [14]

Core Viewpoint - Acadia Pharmaceuticals (ACAD) has shown a recent price increase of 7.8% over the past four weeks, with a mean price target of $29.35 indicating a potential upside of 27.7% from its current price of $22.99 [1] Price Targets and Analyst Consensus - The average price target consists of 20 estimates ranging from a low of $17.00 to a high of $39.00, with a standard deviation of $5.55, indicating variability among analysts [2] - The lowest estimate suggests a decline of 26.1%, while the highest indicates a potential upside of 69.6% [2] - A low standard deviation signifies a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about ACAD's earnings prospects, as indicated by a trend of upward revisions in EPS estimates, which historically correlates with stock price movements [11] - Over the last 30 days, two earnings estimates have increased, leading to a 0.5% rise in the Zacks Consensus Estimate for the current year [12] - ACAD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely predict actual stock price movements accurately [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Monopar Therapeutics Inc. (MNPR) has seen a 21.2% increase in share price over the past four weeks, closing at $77.15, with a potential upside of 42.5% based on Wall Street analysts' mean price target of $109.91 [1][4]. Price Targets - The average of 11 short-term price targets ranges from a low of $85.00 to a high of $142.00, with a standard deviation of $17, indicating variability among analysts [2]. - The lowest estimate suggests a 10.2% increase from the current price, while the highest estimate indicates an 84.1% upside [2]. Analyst Consensus and Earnings Estimates - Analysts are increasingly optimistic about MNPR's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which historically correlate with stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has risen by 5.9% over the past month, with five estimates increasing and no negative revisions [12]. Zacks Rank - MNPR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside [13]. Caution on Price Targets - While price targets are a common metric for investors, they should be approached with skepticism as they can often mislead, and analysts may set overly optimistic targets due to business incentives [3][7][10].

Core Viewpoint - Day One Biopharmaceuticals, Inc. (DAWN) shows significant upside potential with a mean price target of $24.56, indicating a 241.6% increase from its current price of $7.19 [1] Price Targets and Analyst Consensus - The average price target consists of nine estimates ranging from a low of $16.00 to a high of $34.00, with a standard deviation of $5.36, suggesting a high degree of variability among analysts [2] - The lowest estimate indicates a potential increase of 122.5%, while the most optimistic estimate suggests a 372.9% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about DAWN's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.4%, with one estimate moving higher and no negative revisions [12] - DAWN holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after, they can mislead investors, as empirical research indicates that they rarely predict actual stock price movements accurately [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors should approach price targets with skepticism and not rely solely on them for investment decisions [10]